{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:13:49Z","timestamp":1776352429414,"version":"3.51.2"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.iac.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:21:20Z","timestamp":1775096480000},"page":"385-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mast Cell Activation Syndrome and Mimickers"],"prefix":"10.1016","volume":"46","author":[{"given":"Curie","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar Alberto","family":"Galv\u00e1n Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.iac.2026.01.014_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.anai.2023.08.596","article-title":"Neuroimmunology as the next frontier","volume":"131","author":"Shaker","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaci.2024.05.025","article-title":"Mast cell activation syndrome: current understanding and research needs","volume":"154","author":"Castells","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI mast cell disorders committee work group report: Mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaip.2025.10.046","article-title":"Diagnosis and management of patients with mast cell activation syndromes: status 2026","volume":"14","author":"Akin","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2026.01.014_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/ACI.0000000000000768","article-title":"Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review","volume":"21","author":"Sabato","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2500\/aap.2025.46.240088","article-title":"Appraisal of the evidence linking hereditary \u03b1-tryptasemia with mast cell disorders, hypermobility and dysautonomia","volume":"46","author":"Lyons","year":"2025","journal-title":"Allergy Asthma Proc"},{"issue":"8","key":"10.1016\/j.iac.2026.01.014_bib7","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global classification of mast cell activation disorders: an ICD-10-CM-Adjusted proposal of the ECNM-AIM consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaip.2019.08.022","article-title":"Mast cell activation syndrome: tools for diagnosis and differential diagnosis","volume":"8","author":"Weiler","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"9","key":"10.1016\/j.iac.2026.01.014_bib10","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.jaip.2021.12.031","article-title":"Elevated basal serum tryptase: disease distribution and variability in a regional health system","volume":"10","author":"Waters","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2026.01.014_bib12","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jaip.2022.03.008","article-title":"Nontryptase urinary and hematologic biomarkers of mast cell expansion and mast cell activation: status 2022","volume":"10","author":"Butterfield","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2026.01.014_bib13","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib14","first-page":"27","article-title":"Biomarkers in the diagnosis of mast cell activation","volume":"25","author":"Voelker","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11882-024-01128-y","article-title":"Urine mast cell mediators in the evaluation and diagnosis of mast cell activation syndrome","volume":"24","author":"Voelker","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1023\/A:1018886423475","article-title":"Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls","volume":"42","author":"Bischoff","year":"1997","journal-title":"Dig Dis Sci"},{"issue":"12","key":"10.1016\/j.iac.2026.01.014_bib17","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2002.07028.x","article-title":"Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease","volume":"97","author":"Winterkamp","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.iac.2026.01.014_bib18","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/PL00000171","article-title":"Methylhistamine in Crohn\u2019s disease (CD): increased production and elevated urine excretion correlates with disease activity","volume":"49","author":"Weidenhiller","year":"2000","journal-title":"Inflamm Res"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jaci.2025.05.019","article-title":"Chronic spontaneous urticaria and chronic inducible urticaria","volume":"156","author":"Lee","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jaci.2024.02.005","article-title":"Mast cell-sensory neuron crosstalk in allergic diseases","volume":"153","author":"Bao","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.01.014_bib22","article-title":"Mast cell-neuron axis as a core mechanism in chronic pruritus of atopic dermatitis: from mechanistic insights to therapeutic targets","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.anai.2023.10.032","article-title":"Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation","volume":"132","author":"Theoharides","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.iac.2026.01.014_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaci.2014.07.036","article-title":"Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses","volume":"135","author":"Sumpter","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","article-title":"Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists","volume":"154","author":"Wollam","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"7542","key":"10.1016\/j.iac.2026.01.014_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.iac.2026.01.014_bib28","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3389\/fimmu.2018.03027","article-title":"Mas-related G protein-coupled Receptor-X2 (MRGPRX2) in drug hypersensitivity reactions","volume":"9","author":"Porebski","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaci.2021.03.049","article-title":"Multifaceted MRGPRX2: new insight into the role of mast cells in health and disease","volume":"148","author":"Roy","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2026.01.014_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676354","article-title":"MRGPRX2 and adverse drug reactions","volume":"12","author":"McNeil","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.iac.2026.01.014_bib31","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gutjnl-2024-334037","article-title":"Characterisation of MRGPRX2(+) mast cells in irritable bowel syndrome","volume":"74","author":"Decraecker","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.iac.2026.01.014_bib32","doi-asserted-by":"crossref","first-page":"1726096","DOI":"10.3389\/falgy.2025.1726096","article-title":"MRGPRX2-expressing mast cells are increased in the GI tract of individuals with active inflammatory bowel disease and hereditary \u03b1-tryptasemia","volume":"6","author":"Galeas-Pena","year":"2026","journal-title":"Front Allergy"},{"key":"10.1016\/j.iac.2026.01.014_bib33","article-title":"Emerging IgE and non-IgE targeted therapies for chronic urticaria","author":"Chhiba","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.iac.2026.01.014_bib34","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.jaip.2025.07.025","article-title":"Pathogenesis of chronic spontaneous urticaria with or without angioedema","volume":"13","author":"Saini","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2026.01.014_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1513199","article-title":"Association of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patients; prevalence, overlap and response to therapy depends on the definition","volume":"16","author":"Yao","year":"2025","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12026-025-09661-2","article-title":"Dysautonomia: a common comorbidity of systemic disease","volume":"73","author":"Blitshteyn","year":"2025","journal-title":"Immunol Res"},{"issue":"11","key":"10.1016\/j.iac.2026.01.014_bib37","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.jaip.2023.09.014","article-title":"The long road of long COVID: specific considerations for the allergist\/immunologist","volume":"11","author":"Bellanti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2026.01.014_bib38","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review","volume":"9","author":"G\u00fclen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11882-024-01126-0","article-title":"Using the right criteria for MCAS","volume":"24","author":"Gulen","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"issue":"11","key":"10.1016\/j.iac.2026.01.014_bib40","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s11910-023-01307-w","article-title":"Dysautonomia, hypermobility spectrum disorders and mast cell activation syndrome as migraine comorbidities","volume":"23","author":"Blitshteyn","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"10.1016\/j.iac.2026.01.014_bib41","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2024.09.006","article-title":"Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria","volume":"155","author":"Solomon","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib43","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2500\/aap.2026.47.250090","article-title":"Scroll, like, diagnose? Evaluating mast cell activation syndrome information on TikTok","volume":"47","author":"Gansert","year":"2026","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.iac.2026.01.014_bib44","article-title":"Utility of quantifying mast cells in gastrointestinal biopsies in patients with suspected mast cell activation disorder","author":"Odin","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib45","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jaci.2021.06.030","article-title":"Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: a Work Group Report of the AAAAI Allergic Skin Diseases Committee","volume":"148","author":"Zimmermann","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib46","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.5858\/arpa.2023-0070-OA","article-title":"Quantification of mucosal mast cells in the gastrointestinal tract: a primer for practicing pathologists","volume":"148","author":"Genta","year":"2024","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.iac.2026.01.014_bib47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.cgh.2025.02.015","article-title":"AGA clinical practice update on GI manifestations and autonomic or immune dysfunction in hypermobile Ehlers-Danlos syndrome: expert review","volume":"23","author":"Aziz","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaip.2023.10.045","article-title":"Standardized quantification of mast cells in the gastrointestinal tract in adults","volume":"12","author":"Iding","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.iac.2026.01.014_bib49","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.jaip.2024.03.019","article-title":"Beyond confirmed mast cell activation syndrome: approaching patients with dysautonomia and related conditions","volume":"12","author":"Conway","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2026.01.014_bib50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1080\/00016480600704072","article-title":"Dysautonomia rhinitis: associated otolaryngologic manifestations and characterization based on autonomic function tests","volume":"126","author":"Elsheikh","year":"2006","journal-title":"Acta Otolaryngol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.pop.2024.02.006","article-title":"Autonomic dysfunction from diagnosis to treatment","volume":"51","author":"Peltier","year":"2024","journal-title":"Prim Care"},{"key":"10.1016\/j.iac.2026.01.014_bib52","article-title":"Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome","volume":"48","author":"Weinstock","year":"2025","journal-title":"Brain Behav Immun Health"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ACI.0000000000001136","article-title":"Environmental exposures, epithelial barrier dysfunction, and the evolving landscape of allergic disorders and asthma","volume":"26","author":"Fenner","year":"2026","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3.4","key":"10.1016\/j.iac.2026.01.014_bib54","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2152\/jmi.64.296","article-title":"Levetiracetam improves symptoms of multiple chemical sensitivity: case report","volume":"64","author":"Kakisaka","year":"2017","journal-title":"J Med Investig"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.hlc.2025.09.004","article-title":"Postural orthostatic tachycardia syndrome: a state-of-the-art review","volume":"35","author":"Lau","year":"2026","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.iac.2026.01.014_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1648702","article-title":"Neurobiological and neuropsychological disturbance in EDS","volume":"16","author":"Westerman","year":"2025","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajmg.c.31538","article-title":"Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history","volume":"175","author":"Tinkle","year":"2017","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"5","key":"10.1016\/j.iac.2026.01.014_bib58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/ard.32.5.413","article-title":"Articular mobility in an African population","volume":"32","author":"Beighton","year":"1973","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.iac.2026.01.014_bib59","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/rheumatology\/kex043","article-title":"Beighton scores and cut-offs across the lifespan: cross-sectional study of an Australian population","volume":"56","author":"Singh","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41572-020-0194-9","article-title":"The ehlers-danlos syndromes","volume":"6","author":"Malfait","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.iac.2026.01.014_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2025.100111","article-title":"Hypermobile Ehlers-Danlos Syndrome: cerebrovascular, autonomic and neuropathic features","volume":"14","author":"Novak","year":"2025","journal-title":"Am J Med Open"},{"key":"10.1016\/j.iac.2026.01.014_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.874840","article-title":"Mechanobiology in the comorbidities of ehlers Danlos syndrome","volume":"10","author":"Royer","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/aap.2021.42.210022","article-title":"The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome","volume":"42","author":"Wang","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"16","key":"10.1016\/j.iac.2026.01.014_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168429","article-title":"Immunometabolic modulatory role of naltrexone in BV-2 microglia cells","volume":"22","author":"Ku\u010di\u0107","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.iac.2026.01.014_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021002","article-title":"Mast cell activation disorder and postural orthostatic tachycardia syndrome: a clinical association","volume":"10","author":"Kohno","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib66","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjhp.12700","article-title":"Exploring the complexities of illness identity and symptom management in seeking a diagnostic label of postural orthostatic tachycardia syndrome (POTS): an inductive approach","volume":"29","author":"Knoop","year":"2024","journal-title":"Br J Health Psychol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/CS20120276","article-title":"Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics","volume":"124","author":"Plash","year":"2013","journal-title":"Clin Sci (Lond)"},{"issue":"11","key":"10.1016\/j.iac.2026.01.014_bib68","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jacc.2018.05.079","article-title":"Orthostatic hypotension: JACC state-of-the-art review","volume":"72","author":"Freeman","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10840-017-0225-y","article-title":"Effects of intermittent intravenous saline infusions in patients with medication-refractory postural tachycardia syndrome","volume":"48","author":"Ruzieh","year":"2017","journal-title":"J Interv Card Electrophysiol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib70","article-title":"Ivabradine in postural orthostatic tachycardia syndrome: a review of the literature","volume":"12","author":"Tahir","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib71","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"12","key":"10.1016\/j.iac.2026.01.014_bib72","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1016\/j.jaip.2025.10.018","article-title":"Alpha-tryptase overexpression as a modifier of mast cell-mediated reactions","volume":"13","author":"Koro\u0161ec","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2026.01.014_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2025.1599358","article-title":"Utility of tryptase genotyping in the screening, diagnosis, and management of systemic mastocytosis","volume":"6","author":"McMurray","year":"2025","journal-title":"Front Allergy"},{"issue":"5","key":"10.1016\/j.iac.2026.01.014_bib74","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ACI.0000000000000849","article-title":"Hereditary alpha-tryptasemia","volume":"22","author":"Bonadonna","year":"2022","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib75","doi-asserted-by":"crossref","first-page":"152","DOI":"10.23822\/EurAnnACI.1764-1489.288","article-title":"Defining hereditary alpha-tryptasemia as a risk\/modifying factor for anaphylaxis: are we there yet?","volume":"55","author":"Couto","year":"2023","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib76","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib77","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/all.15911","article-title":"Clinical impact of the TPSAB1 genotype in mast cell diseases: a REMA study in a cohort of 959 individuals","volume":"79","author":"Gonz\u00e1lez-de-Olano","year":"2024","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib78","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib79","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib80","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2023.08.015","article-title":"Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes","volume":"153","author":"Polivka","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib81","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2022.09.038","article-title":"Disease correlates and clinical relevance of hereditary \u03b1-tryptasemia in patients with systemic mastocytosis","volume":"151","author":"Sordi","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11882-024-01136-y","article-title":"Alpha-tryptase as a risk-modifying factor for mast cell-mediated reactions","volume":"24","author":"Shin","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"issue":"11","key":"10.1016\/j.iac.2026.01.014_bib83","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1111\/all.16185","article-title":"A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma","volume":"79","author":"Madrange","year":"2024","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2026.01.014_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12016-025-09063-0","article-title":"Describing clinical characteristics and treatment course of patients with hereditary alpha-tryptasemia: a single-center study","volume":"68","author":"Matheny","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.anai.2021.10.006","article-title":"Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy","volume":"128","author":"Novak","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.iac.2026.01.014_bib86","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000524532","article-title":"Mast cell activation syndromes: collegium internationale allergologicum update 2022","volume":"183","author":"Valent","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.iac.2026.01.014_bib87","doi-asserted-by":"crossref","first-page":"461","DOI":"10.18176\/jiaci.0675","article-title":"Clinical approach to mast cell activation syndrome: a practical overview","volume":"31","author":"Matito","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2026.01.014_bib88","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/cea.14264","article-title":"Clonal mast cell disorders and hereditary \u03b1-tryptasemia as risk factors for anaphylaxis","volume":"53","author":"Ka\u010dar","year":"2023","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.iac.2026.01.014_bib89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11882-023-01122-w","article-title":"Predictors of clonality and underlying mastocytosis in mast cell activation syndromes","volume":"24","author":"Gonzalez-de-Olano","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"10.1016\/j.iac.2026.01.014_bib90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:32:03Z","timestamp":1776349923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856126000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0889856126000147"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2026.01.014","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast Cell Activation Syndrome and Mimickers","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}